Cost of albumin
The cost of albumin versus crystalloids was also considered. Luciano Gattinoni, M.D., University of Milan, framed the cost issue in this way: "Good medicine means good economy, not vice versa. When physicians are pressed to save money, the potential for complications and adverse events increases."
This Dialogue is the most recent in CSL Behring's ongoing series that analyzes critical issues around human plasma-derived and recombinant coagulation factor therapies for patients, caregivers and healthcare providers.
Garrett E. Bergman, M.D., CSL Behring's Senior Director, Medical Affairs North America, said the Dialogue provided important insights. "Because of our varied disciplines, we've achieved a cross-pollination of ideas that is truly unique," Dr. Bergman said. "As Dr. Bernardi observed during the Dialogue, the fact that we can discuss our respective problems and find so many common points of interest is unusual. It's not often that a pathologist and an intensivist have the opportunity to sit down and exchange ideas and experiences."
About CSL Behring
CSL Behring, a leader in the plasma protein therapeutics industry, has provided the international community with albumin for over 50 years. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide.
CSL Behring therapies are used around the world to treat coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation and burn treatment, and to prevent hemolytic disease of the newborn.
CSL Behring operates one of the world's largest plasma collection networ
|SOURCE CSL Behring|
Copyright©2010 PR Newswire.
All rights reserved